TheProfitWatch

URGN - UroGen Pharma Ltd. Ordinary Shares

Day 1m 10m 60m PreMarket Market AfterHours Gap
25.0 0.88 (3.52%) -0.02 (-0.06%) -0.01 (-0.02%) -0.18 (-0.69%) -0.11 (-0.44%) 1.16 (4.69%) --- -0.11 (-0.44%)

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-1.05
Diluted EPS:
Basic P/E:
-24.6476
Diluted P/E:
RSI(14) 1m:
56.52
VWAP:
25.88
RVol:

Events

Period Kind Movement Occurred At

Related News